Previous reports from our laboratory have demonstrated the stimulation of specific suppressor T cells in genetic nonresponder mice after immunization with the terpolymer of L-glutamic acid, L-alanine, and L-tyrosine (GAT) (1, 2) and with the copolymer of Lglutamic acid and L-tyrosine (GT) (3-5). These findings raise two important questions: (a) do the specific suppressor T cells inhibit an antibody response which would otherwise develop in nonresponder mice; and, (b) can specific helper T-cell activity be detected in these animals. Responsiveness appears to be completely dominant over suppression in (responder × suppressor)F1 hybrids, therefore, we have been unable to detect suppressor cells in these hybrids after conventional immunization with GAT (2). However, using special conditions of antigen administration, GAT helper activity could be demonstrated in nonresponder DBA/1 ("suppressor") mice. Thus, GAT-specific helper activity was not detected in these nonresponder animals after immunization with GAT irrespective of the adjuvant used, but could be stimulated by macrophage-bound GAT or by GAT cemplexed with methylated bovine serum albumin GAT-MBSA (6).
In the current report we have taken advantage of the fact that suppressor Tcell activity is more sensitive to cyclophosphamide treatment than T-cell helper activity (7) to demonstrate the presence of GT-specific helper activity in "nonrespondee' BALB/c mice. We describe: (a) the dose of cyclophosphamide and conditions of treatment which inhibits the well-documented stimulation of specific suppressor T cells in BALB/c mice injected with GT previous to immunization with GT-MBSA, and (b) the ability of cyclophosphamide to permit the development of primary PFC responses to GT in these "nonresponde~' mice.
These cyclophosphamide-induced responses are not characterized by the high levels of antibody detected in genetic responder animals.
Materials and Methods
Mice. The mice were purchased from The Health Research Laboratories, Buffalo, N. Y., or were bred in our animal facilities.
Antigens. The antigens and hemolytic plaque assay used in these experiments are the same as those described in the companion paper (5) .
Immunization and Treatment with Cyclophosphamide. Cyclophosphamide (Cytoxan) was purchased from Mead-Johnson Laboratories, Evansville, Ind. The drug was administered intraperitoneally in the dose of 200 mg/kg. To investigate the effect of the drug on the suppressive activity of * Supported by Grant AI-09920 from the National Institutes of Health.
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GT, BALB/c mice were injected intraperitoneally with cyclophosphamide followed 2 days later with 100 ~g GT in a mixture of magnesium and aluminum hydroxides (Maalox, William H. Rorer, Inc., Fort Washington, Pa.) or with Maalox alone. 10 days later, the mice were immunized intraperitoneally with 10 pg of GT as GT-MBSA emulsified in an equal volume of complete Freund's adjuvant (CFA) (Difco Laboratories, Detroit, Mich.). To study the effect ofcyclophosphamide on responsiveness to GT, other groups of BALB/c mice were injected with the drug or with physiological saline intraporitoneally (Group V and VI of Table I ) and 12 days later immunized with 100 ~g GT in CFA.
GT-Specific Suppressor Extract and Control Maalox Extract.
GT-specific suppressor extract was prepared by ultransonification and ultracentrifugation of thymocytes and spleen cells from BALB/c mice immunized 3 days previously with 100 ~g GT in Maalox, as described previously (8, 9) . As control, an extract referred to as Maalox extract was prepared similarly from cells of animals injected with Maalox alone. The details of the preparations and the properties of the GTspecific suppressor factor on the primary PFC response of BALB/c to GT-MBSA will be described separately. I The GT-spocific suppressor extract behaved like the GAT-specific suppressor factor(s) previously described by this laboratory (9).
Antigen-Binding Assay. The humoral response to GT was measured by antigen-binding assay employing the homologous GT copolymer. GT was iodinated by the chloramine-T method with carrier-free '2'~I (New England Nuclear, Boston, Mass.) and separated from inorganic iodide by passage over 0.5 x 25-cm columns of Sephadex G-25F (Pharmacia Fine Chemicals, Piscataway, N. J.). Serum samples diluted 1:5 with phosphate-buffered saline were assayed by modified Farr assay which has been described previously (10).
Results and Discussion As shown in Table I , 12 days were allowed to elapse between treatment with cyclophosphamide and immunization with GT-MBSA to permit recovery of Bcell function. The comparable responses of Group I and III indicate that cyclophosphamide in the dose and time used did not affect the primary response to GT-MBSA when assayed 7 days later. The suppressive effects normally induced by GT preimmunization, however, were completely abolished by this treatment (compare Groups I and II and II and IV, respectively). This effect may be interpreted to reflect the inhibitory activity of the drug on the stimulation of GTspecific suppressor T cells.
But the most interesting result is the development of GT-specific primary IgG responses in animals treated with cyclophosphamide 12 days earlier (Groups V and VI). The response to GT immunization after this treatment were unequivocal and did not differ significantly from the responses of control mice to GT-MBSA (Groups I and VI); however, no specific IgM responses have been detected in animals treated with cyclophosphamide.
The antigen-binding values of the sera from animals treated with cyclophosphamide presented in Table II show that the responses to GT in these animals are seen early after primary immunization and do not progress in spite of secondary challenge. On the whole, these responses are considerably weaker than are observed in genetic responder (C3H x GT Swiss responder)F, mice not treated with cyclophosphamide. The reason for the limited anti-GT responses observed may be the weak responsiveness of the BALB/c animals or the recovery of suppressor cell activity after the cyclophosphamide treatment or both. Responsiveness to GT is only observed in some Swiss mice (3) . The data in Table II on the responses of (C3H x GT Swiss responder)F, mice, which segregate into ' Debre, P., C. Waltenbaugh, and B. Benacerraf. Manuscript in preparation. equal numbers of responders and nonresponders, demonstrate that the parental Swiss responder mice were heterozygous for the GT gene(s).
TABLE II Effect of Cyclophosphamide on GT Antibody Responses in BALB/c Mice
The demonstration of the suppressor activity for the GT-MBSA responses of extracts prepared from thymus and spleen cells of GT-primed mice' raised the question whether treatment with cyclophosphamide inhibits the stimulation of suppressor activity or renders the cells of the immune spleen insensitive to the suppressive activity of the GT-specific "suppressor factor." This issue was explored in the experiments in Table III. BALB/c mice were injected with 0.5 ml of 1/2 dilution of extracts prepared from 3 x 10 s thymus and spleen cells/ml from animals immunized with 100 fig GT in Maalox or Maalox alone 3 days previously. The extracts were injected intravenously on the day when the animals were immunized with GT-MBSA. The data show that cyclophosphamide treatment inhibits GT-specific suppression normally caused by GT preimmunization but not by the injection of GTspecific suppressor extracts. The suppressive activity observed in the normal animals treated with suppressor extract was greater than that seen in animals treated with cyclophosphamide. However, the difference between Groups IV and VI was not statistically significant.
The results of these experiments imply that the helper and suppressor activity for distinct thymus-dependent antigens is under a delicate balance controlled by genes within the I region of the H-2 complex. The critical problem remaining to be resolved is the mechanism whereby specificity for the antigens is manifested by the processes controlled by individual Ir and Is genes, which have been shown to regulate immune responses to thymus-dependent antigens.
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